Hereditary Sensory and Autonomic Neuropathy Type 2 Overview
Learn About Hereditary Sensory and Autonomic Neuropathy Type 2
- Hereditary sensory and autonomic neuropathy type 2
- Giaccai type acroosteolysis
- HSAN2
- Hereditary sensory neuropathy type 2
- Hereditary sensory radicular neuropathy, recessive form
- Morvan disease
- Neurogenic acroosteolysis
- Neuropathy, congenital sensory
- Neuropathy, progressive sensory, of children
Dysautonomia Center Llp
Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is rated as an Elite provider by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Orthostatic Hypotension.
Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.
Ingo Kurth practices in Aachen, Germany. Mr. Kurth is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory and Autonomic Neuropathy Type 2. His top areas of expertise are Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, Hereditary Sensory Neuropathy Type 1 (HSN1), Anhidrosis, and Bone Marrow Transplant.
Summary: This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn mo...
Summary: Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center